Tibco Sees Rise in Spotfire Revenues in Q4; Projects 30-Percent Growth in 2008 | GenomeWeb
Tibco’s acquisition of Spotfire last year is driving a healthy increase in the company’s life science revenues, a company official told BioInform this week.
 
Roger Oberg, vice president of product strategy for Tibco’s Spotfire unit, said that the company expects that “the life sciences business is going to grow for the Spotfire [line],” and estimated that the Spotfire life sciences business “is going to grow over 30 percent in 2008.”
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.